Revolutionary Technology Set to Disrupt the Rapidly Growing $4.1 Billion Breast Imaging Market

Breast cancer is one of the most devastating – and widespread – diseases on the planet, with more than 1.7 million new cases diagnosed every year.

There are currently four common methods for detecting breast cancer recommended by doctors, the most common of which is mammography.

As you might expect, the market for breast imaging via these existing methods is massive – projected to reach $4.14 billion by 2021 and $7.3 billion by 2024.

But in spite of this rapid growth, there are serious flaws with each of the existing imaging methods – including high cost…false positives…false negatives…and painful imaging processes.

One company – Canadian-based Izotropic Corporation (CSE: IZO); (OTC: IZOZF); (FRA: 1R3) – is now working to bring to market a revolutionary breast imaging technology that could change the landscape for breast cancer detection in a powerful way.

This new technology – known as Breast CT – appears poised to bring massive disruption to the $4.14 billion breast imaging market.

Investors should consider this an opportunity to get in early with a company that possesses a truly disruptive technology…one that is already being tested in ongoing, fully funded clinical trials.

And this is not technology that is still on a drawing room table.

To date, nearly two decades’ worth of research and development – as well as nearly US$20 million in funding – have been invested into developing this groundbreaking breast CT imaging technology…and a fully funded, $3 million clinical trial is already underway.

Superior Results: How the Izotropic Breast Imaging System is Redefining Breast Cancer Detection

The simplest way to understand the key advantage of Breast CT over traditional mammography is that Breast CT offers true 3-D imaging while standard x-rays or mammography offers only 2-D imaging.

With the Izotropic Breast Imaging System, women lay face down on the system table placing the breast to be imaged in a hole in the table.

The imaging hardware beneath the table circles around the breast creating a series of raw data images. These raw images are processed through the computer to reconstruct true 3-D images of the breast.

The Izotropic Breast Imaging System provides true 3-D imaging with a 360° view acquisition. With breast CT, identifying tumors and determining their size, shape, location and depth is made easier with multiple viewpoints.

With the Izotropic Breast Imaging System, a patient scan is completed in just 10 seconds – and over 500 images are captured in that time.

More importantly, results of images taken on hundreds of patients during clinical trials at UC Davis Medical Center show that the most recent model of the Izotropic Breast Imaging System is superior to the current modalities when used with contrast.

Early Detection is the Key to Success in the Fight Against Breast Cancer

There’s no question that early detection is critical to reducing the likelihood of death in women who are ultimately diagnosed with breast cancer.

The Izotropic Breast Imaging System provides the best practices for early detection of breast cancer because of the following:

With false negatives being one of the largest – and most costly – drawbacks of existing technologies, this superiority is critical.

The average woman is currently 62 years old when her breast cancer is discovered. But in many cases, that discovery is made too late.

The Izotropic Breast Imaging System has the ability to detect much smaller lesions – and up to a full year earlier than technology being widely used today.

Truly Disruptive Technology Could Mean Significant Upisde Potential for Early Investors

The term “disruptive” gets thrown around a lot when it comes to new technologies – and it’s often not accurate.

But in the case of the Izotropic Breast Imaging System, this is a truly disruptive technology as it has the potential to replace all of the existing methods used for breast cancer detection.

At this very moment, Izotropic Corporation (CSE: IZO); (OTC: IZOZF); (FRA: 1R3) is a company with a modest market cap that is flying beneath Wall Street’s radar.

But as word begins to spread about the results the company is getting with its Izotropic Breast Imaging System, discussion about Izotropic Corporation could spread quickly – making the company a particularly attractive potential takeover candidate.

The Breast Imaging Market is Growing Rapidly, Making Izotropic’s Disruptive Technology Even More Critical

Because of rapid population growth and an increased emphasis on early detection and screening, the breast imaging market is projected to grow at a rapid rate.

According to a report from Grandview Research, the market is expected to reach $4.14 billion by 2021 and grow at a CAGR (compound annual growth rate) of 8.0%, eventually reaching $7.3 billion by 2024.ⁱⁱⁱ

Thanks to the ease of use, comfort and accuracy associated with the Izotropic Breast Imaging System, all women who are due for breast imaging could potentially be a driver for growth of Izotropic’s technology.

But another potential growth driver could be insurance companies frustrated with the high cost associated with false positives.

A false positive determination results in call backs and additional workups – including additional screening (increased radiation exposures) and diagnostic imaging, and biopsies – that ultimately prove costly and unnecessary.

One study, published in 2017, states that “follow-up breast diagnostic procedures amounted to an annual expenditure of $7.91 billion…underscoring the need for diagnostic modalities providing better specificity and greater diagnostic confidence.”^iv

Approximately 1.6 million breast biopsies are performed in the United States each year, and hospitals typically charge $5,000 to $6,000 per biopsy…meaning that false positive breast biopsies cost the healthcare industry – and patients – as much as $2.18 billion annually.^v

Outstanding Leadership Helps Make Izotropic Corporation (CSE: IZO); (OTC: IZOZF); (FRA: 1R3) a Potential High-Upside Investment Opportunity

The leadership team helping turn Izotropic’s potentially disruptive technology into a successful business venture includes a number of executives with decades of leadership experience as well as expertise in the field.

In particular, CEO Bob Thast possesses more than three decades of experience in executive positions and board chairman with a number of publicly listed companies and he has an outstanding track record of delivering value for shareholders.

Izotropic’s principal founder, John Boone, has 32 years of experience in academia and has been involved in breast imaging technology for the better part of two decades. Mr. Boone was last year awarded the 2019 William D. Coolidge award for lifetime achievement in medical physics.

The management team:

Robert (Bob) Thast – Chief Executive Officer

Has served as board chairman, chief executive officer, senior executive, and director to several publicly listed companies. Has expertise in a number of fields including capital markets, company management, strategic planning, business development, and corporate governance.

John M. Boone – Ph.D., Principal Founder, Director

Boone is a medical physicist with 32 years’ experience in academia and has been the principal investigator of the Breast Tomography Project at UC Davis for the past 18 years. He is a professor of radiology and biomedical engineering, and recently served as the president of the American Association of Physicists in Medicine.

Jody Bellefleur – CPA, CGA, CFO

Has over 25 years’ experience as a corporate accountant, focussing exclusively on public companies for the last 10 years. She is responsible for all aspects of regulatory financial reporting including the preparation of quarterly financial statements, management discussion and analysis reports, the coordination of annual audits, and government tax and regulatory reporting.

Marshall (Terry) Severyn – Vice President of Marketing, Director

With over 30 years of experience in corporate sales and marketing, he has successfully led teams of up to 1,000+ employees in the pharmaceutical and high-tech sectors.

Ali Sodagar – Legal Advisor, Director

Founder of multidisciplinary law firm Sodagar & Company Law Corp., Sodagar specializes in business and commercial law, intellectual property, trademark, copyright, and licensing law. He also holds a bachelor’s degree in medical and health physics.

Ralph Proceviat – Director

Mr. Proceviat has more than 35 years in business, finance, markets and operations spanning several industries operating in Canada, Europe and the United States. He is a member of the Chartered Professional Accountants of BC and holds a Bachelor of Commerce Degree in Management Information Systems from the University of British Columbia.

John McGraw – Ph.D., Medical Device Business Consultant

Mr. McGraw has 21 years experience in heath care business development and has created and implemented successful strategies for the advancement clinical trials and medical device development through licensing and acquisitions.

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. WallStreetNation.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for by Izotropic Corporation in an effort to enhance public awareness of Izotropic Corporation and its securities. Winning Media has or expects to receive over one thousand dollars by Izotropic Corporation as a total budget for this advertising effort on CPC campaign. Neither WallStreetNation.com or Winning Media currently holds the securities of Izotropic Corporation . and does not currently intend to purchase such securities. This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at the SEC’s EDGAR page. WallStreetNation.com is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.